Method for measuring relative abundance of specific cell subpopulation within CD4+t cell population

The method and kit for measuring CD4+ T cell subpopulations using whole blood samples at varying temperatures for extended periods address inefficiencies in existing methods, providing stable and accurate results for cancer therapy responsiveness assessments.

JP2024157603AActive Publication Date: 2024-11-08IMMUNIT RES INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2023072026
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-26
Publication Date
2024-11-08
Estimated Expiration
2043-04-26

AI Technical Summary

Technical Problem

Existing methods for measuring the relative abundance of specific CD4+ T cell subpopulations, such as CCR4-CCR6+ cells, are inefficient and require specialized equipment and skilled personnel, leading to variability in results due to differences in sample handling and storage conditions.

Method used

A method and kit for measuring CD4+ T cell subpopulations using whole blood samples, allowing storage at temperatures between 10°C to 40°C for up to 6 days, which enables accurate determination of CCR4-CCR6+ and CXCR3-CCR4+ cell subpopulations without the need for immediate processing or specialized equipment.

Benefits of technology

This approach allows for more stable and accurate measurement of medically important CD4+ T cell subpopulations, reducing variability and enabling sample collection and analysis at non-specialized locations, thus improving the efficiency and reliability of cancer therapy responsiveness assessments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024157603000005
    Figure 2024157603000005
  • Figure 2024157603000006
    Figure 2024157603000006
  • Figure 2024157603000007
    Figure 2024157603000007
Patent Text Reader

Abstract

To provide a method for more efficiently measuring a relative amount of a specific cell subpopulation in a CD4+T cell population, and a kit therefor.SOLUTION: The present invention provides a method for determining a relative amount of a CCR4-CCR6+ cell subpopulation in a CD4+ T cell population in a sample from a subject, comprising the steps of: selecting a CXCR3- cell subpopulation within the CD4+ T cell population; establishing a boundary between a CCR4- cell subpopulation and a CCR4+ cell subpopulation in the CXCR3- cell subpopulation; and measuring the relative amount of the CCR4-CCR6+ cell subpopulation within the CD4+ T cell population by using the boundary.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for the treatment of + For determining the relative abundance of medically important cell subpopulations in a T cell population. [Background technology]

[0002] CD4 + It is known that there are several medically important cell populations within the T cell population. For example, CD4 + CD62L low Cell subpopulations and CCR4 - CCR6 + The relative abundance of cell subpopulations is particularly useful for determining responsiveness to cancer treatments, as are medically important cell subpopulations (Patent Document 1, Patent Document 2).

[0003] These cell subpopulations are typically isolated by drawing at least 8 ml of peripheral blood, and then having an expert in experimental procedures use a centrifuge or other equipment at the site of blood collection to separate and freeze PBMCs (peripheral blood mononuclear cells). The frozen cells are then transported to a measurement facility, where they are stored as necessary after transport, and then cultured, stained, and subjected to FACS measurement. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2018 / 147291 [Patent Document 2] International Publication No. 2022 / 054796 Summary of the Invention [Problem to be solved by the invention]

[0005] The present invention relates to a method for the treatment of + The objective of the present invention is to provide a method for more efficiently measuring the relative amount of a specific cell subpopulation in a T cell population, and a kit therefor. [Means for solving the problem]

[0006] The present inventors have + CCR4 in T cell populations - CCR6 + To measure the relative abundance of cell subpopulations, we first + / - It has been found to be advantageous to separate the cell populations.

[0007] We also successfully detected CD4 + Preferred sample storage conditions have been discovered for determining the relative abundance of specific cell subpopulations within a T cell population.

[0008] For example, the present invention provides the following items. (Item 1) CD4 in a sample from a subject + CCR4 in T cell populations - CCR6 + 1. A method for determining the relative abundance of cell subpopulations, comprising: CD4 + CXCR3 in T cell populations - Selecting a cell subpopulation; CXCR3 - In a subpopulation of cells, CCR4 - Cell subpopulations and CCR4 + establishing boundaries between cell subpopulations; Using the above boundaries, CD4 + CCR4 in T cell populations - CCR6 + Measuring the relative abundance of cell subpopulations. The method includes: (Item 2) 2. The method of claim 1, wherein the sample is a whole blood sample of peripheral blood or a peripheral blood mononuclear cell (PBMC) sample of the subject. (Item 3) 3. The method of claim 2, wherein the sample is a whole blood sample. (Item 4) 4. The method of claim 3, wherein the sample has been stored for one or more days after collection from the subject. (Item 5) 5. The method according to item 4, wherein the sample is stored for 1 to 6 days after collection from the subject. (Item 6) 5. The method according to item 4, wherein the sample is stored for 1 to 3 days after collection from the subject. (Item 7) 5. The method according to item 4, wherein the sample is stored at about 10°C to about 40°C. (Item 8) 5. The method according to item 4, wherein the sample is stored at about 12° C. to about 25° C. (Item 9) 4. The method according to item 3, wherein the sample is about 10 μl to about 500 μl. (Item 10) CD4 in a sample from a subject + CCR4 in T cell populations - CCR6 + 1. A method for determining the relative abundance of cell subpopulations, comprising: providing a whole blood sample from said subject; The CD4 + CCR4 in T cell populations - CCR6 + Measuring the relative abundance of cell subpopulations. The method includes: (Item 11) 11. The method of claim 10, wherein the sample has been stored for one or more days after collection from the subject. (Item 12) Item 12. The method according to item 11, wherein the sample is stored for 1 to 6 days after collection from the subject. (Item 13) Item 12. The method according to item 11, wherein the sample is stored for 1 to 3 days after collection from the subject. (Item 14) Item 12. The method according to item 11, wherein the sample is stored at about 10°C to about 40°C. (Item 15) Item 12. The method according to item 11, wherein the sample is stored at about 12°C to about 25°C. (Item 16) Item 11. The method according to item 10, wherein the sample is about 10 μl to about 500 μl. (Item 17) 17. A kit for use in the method according to any one of items 1 to 16, comprising a detection agent for CD4, a detection agent for CCR4, and a detection agent for CCR6. (Item 18) 18. The kit of item 17, further comprising a detection agent for CXCR3. (Item 19) 17. The kit of item 16, wherein the detection agent is an antibody. Effect of the Invention

[0009] According to the present invention, CD4 + Medically important cell subpopulations within the T cell population (e.g., CCR4 - CCR6 + Cell subpopulations or CD62L low This allows for more accurate measurement of cell subpopulations.

[0010] In addition, this solves the problem of limited locations for blood collection (where there are centrifuges and people with the necessary skills) and the large disparity between facilities with skilled personnel and institutions in separating PBMCs and those that are not, making it possible to obtain samples with little variation between facilities without the hassle of collecting blood. [Brief description of the drawings]

[0011] [Figure 1] Figure 1 shows CXCR3 histograms and scatter plots of CCR4 vs CCR6 in whole blood and PBMCs. [Diagram 2] Figure 2 shows CXCR3 histograms and CCR4 vs. CCR6 scatter plots after varying storage periods of whole blood. [Diagram 3] Figure 3 shows a scatter plot of CD4 vs. CD8 after storage at different temperatures and for different days. [Figure 4] FIG. 4 shows histograms of CD62L relative to CD4+ cells stored at different temperatures for different days. [Diagram 5] FIG. 5 shows histograms of CD62L for CD8+ cells stored at different temperatures for different days. [Figure 6] FIG. 6 shows Th7R when stored at different temperatures for different days. [Figure 7] FIG. 7 shows scatter plots of CCR7 and CD45RA for CD4+ cells stored at different temperatures for different days. [Figure 8] FIG. 8 shows scatter plots of CCR7 and CD45RA for CD8+ cells stored at different temperatures for different days. [Figure 9] FIG. 9 shows a comparison between whole blood and PBMCs separated from stored whole blood and measured after cryopreservation. [Figure 10] FIG. 10 shows a comparison of the expression of CCR4, CCR6, and CXCR3 in CD4+ cells by each preservation method. [Figure 11A] FIG. 11A shows a CCR6 vs. CCR4 scatter plot for CD4+ cells, no gate shown. [Figure 11B] FIG. 11B shows a CCR6 vs. CCR4 scatter plot for CD4+CXCR3- cells, no gate shown. [Figure 11C] FIG. 11C shows a CCR6 vs. CCR4 scatter plot for CD4+ cells, with gates indicated. [Figure 11D] FIG. 11D shows a CCR6 vs. CCR4 scatter plot for CD4+CXCR3- cells, with gates indicated. [Figure 12] FIG. 12 shows the results of WB panel 3 staining of autologous microblood samples. [Figure 13] FIG. 13 is a schematic diagram showing Th differentiation of human CD4 T cells. [Figure 14] FIG. 14 is a schematic diagram showing peripheral blood CD4+ T cell clusters and chemokine receptors expressed in each compartment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] The present disclosure will be described below while showing the best mode. Throughout this specification, the expression of the singular form should be understood to include the concept of the plural form, unless otherwise specified. Therefore, the singular article (for example, in the case of English, "a", "an", "the", etc.) should be understood to include the concept of the plural form, unless otherwise specified. In addition, it should be understood that the terms used in this specification are used in the sense commonly used in the field, unless otherwise specified. Therefore, unless otherwise defined, all technical terms and scientific and technical terms used in this specification have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. In case of conflict, the present specification (including definitions) will take precedence.

[0013] The following provides definitions of terms particularly used in this specification and / or explains basic technical content as appropriate.

[0014] As used herein, "about" means ±10% of the preceding numerical value.

[0015] As used herein, the term "biomarker" refers to a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathological processes, or pharmacological responses to a therapeutic intervention.

[0016] As used herein, "cancer" or "carcinoma" are used interchangeably and refer to a malignant tumor or a state in which such a malignant tumor exists that is highly atypical, grows faster than normal cells, and can destructively invade surrounding tissues or cause metastasis. In the present invention, cancer includes solid cancers and hematopoietic tumors, including, but not limited to, non-small cell lung cancer, small cell lung cancer, renal cancer, Hodgkin's disease, head and neck cancer, breast cancer, gastric cancer, malignant melanoma, colon cancer, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, gastrointestinal stromal tumor, pancreatic neuroendocrine tumor, and skin cancer.

[0017] As used herein, the term "cancer immunotherapy" or "cancer immunotherapy" refers to a method for treating cancer using the body's defense mechanisms, such as the immune system, possessed by an organism.

[0018] As used herein, the term "anti-tumor immune response" refers to any immune response against a tumor in a living body.

[0019] As used herein, "correlate" refers to two events having a statistically significant correlation. For example, "a relative amount of B correlated with A" refers to the occurrence of event A, whereby the relative amount of B is affected (e.g., increased or decreased) in a statistically significant manner.

[0020] As used herein, the term "cell subpopulation" refers to any collection of cells that share some common characteristic in a cell population that contains cells with diverse characteristics. If a specific name is known in the art, such a term can be used to refer to a specific cell subpopulation, or any property (e.g., expression of a cell surface marker) can be described to refer to a specific cell subpopulation.

[0021] As used herein, the term "relative amount" with respect to cells is used interchangeably with "proportion." Typically, the terms "relative amount" and "proportion" refer to the amount of a particular cell population (e.g., CD4 + The number of cells forming a desired cell subpopulation (e.g., CCR4 T cell population) - CCR6 + The term "cell subpopulation" refers to the number of cells that form a pluripotent cell population.

[0022] As used herein, the term "relative value" refers to a value calculated for a given value in comparison with another value.

[0023] As used herein, the term "detection agent" refers broadly to any agent capable of detecting a substance of interest (eg, a cell surface marker, etc.).

[0024] As used herein, the "amount" of a cell subpopulation includes the absolute number of a cell and the relative amount as a percentage of a cell population.

[0025] In this specification, "flow cytometry" refers to a technique for measuring the number of cells, solids, and other biological particles suspended in a liquid, as well as the physical, chemical, and biological properties of each particle. The results of flow cytometry can typically be expressed as a dot plot with FSC on the X-axis and SSC on the Y-axis. Each cell is represented by a dot in the diagram, and their positions are determined by the relative values ​​of FSC and SSC. Lymphocytes, which are relatively small in size and have a simple internal structure, are displayed in the lower left, granulocytes, which are large in size and have granules inside, are displayed in the upper right, and monocytes, which are large in size but have a simple internal structure, are displayed as separate groups between lymphocytes and granulocytes. The results of flow cytometry can also be displayed as histograms or dot plots.

[0026] As used herein, a "subject" can be any animal, typically a mammal. Mammals include, but are not limited to, livestock animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the subject is a human.

[0027] As used herein, the term "cancer therapy" refers to any treatment administered to a cancer patient to remove or shrink a tumor, including, but not limited to, cancer immunotherapy, radiation therapy, molecular targeted drug therapy, surgery, cell transfer, or any combination of these treatments.

[0028] (Th7R) As used herein, the term "effector cells" refers to immune cells that have differentiated from naive cells that have not been stimulated by antigens and have acquired the function of actually acting in immunity. In particular, three types of human helper T cells are known: Th1, Th2, and Th17. Each can release characteristic cytokines such as interferon gamma (IFNγ) and interleukin 17 (IL-17). In addition, there are transcription factors characteristic of each Th subset, such as Th1 expressing T-bet and Th2 expressing GATA-3, but there are also cells that express both T-bet and GATA-3, and such cells are expressed as "Th1 / Th2" or "Th1 / 2". As used herein, "Th1 / Th17" or "Th1 / 17" expresses both T-bet, which is characteristic of Th1, and RORγt, which is characteristic of Th17.

[0029] Effector cells such as Th1, Th2, and Th17 can also be classified according to the type of chemokine receptor (CCR) they express. For example, Th1 expresses CXCR3, Th2 expresses CCR4, and Th17 expresses CCR4 and CCR6. Classification of Th subsets is shown, for example, in Figure 13 (Annual Review of Immunology, Vol. 34: 317-334 Heterogeneity of Human CD4 + T Cells Against Microbes, Fig. 1). In the present specification, "Th1 / Th17" or "Th1 / 17" expresses CXCR3, which is characteristic of Th1, and CCR6, which is one of the two CCRs characteristic of Th17. In the present specification, CCR6 SP (Single positive) is a type that has not been classified in the Th type classification by CCR, and is a Th subset that expresses only CCR6 among CCR4, CCR6, and CXCR3. In the present specification, TP (Triple positive) is a type that has not been classified in the Th type classification by CCR, and is a Th subset that expresses three of CCR4, CCR6, and CXCR3.

[0030] In WO 2022 / 054796, the Th clusters Th1 / 17 and CCR6 SP CD4 + It was found that T cell clusters showed a high correlation with progression-free survival. The chemokine receptors expressed in each compartment are summarized in Figure 14 (corresponding to Figure 17 in WO 2022 / 054796). As is clear from this figure, the area surrounded by the dashed line is CD62L low It can be seen that there are four clusters (C, D, E, H) with different chemokine receptor expression. Of these, cluster D expresses CXCR3 + CCR4 - CCR6 + and compartment H is Th1 / 17, which is represented by CXCR3 - CCR4 - CCR6 + The CCR6 SP is represented by the formula:

[0031] As used herein, "Th7R" refers to the Th1 / 17 cell subpopulation (CD4 + CXCR3 + CCR4 - CCR6 + ) and the CCR6 SP cell subpopulation (CD4 + CXCR3 - CCR4 - CCR6 + ) The blood Th7R cell subpopulation is thought to be involved in systemic immunity, and can be used to predict the effectiveness of cancer immunotherapy, particularly immune checkpoint inhibitors (anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, etc.), and to predict responses to cancer treatments such as chemoradiotherapy or molecular targeted drugs (e.g., epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors). It is also a medically important cell subpopulation, as it is found in patients with hepatitis B, mouse models of chlamydia lung infection, patients with opportunistic infections, patients with dengue fever, and patients with acetylcholine antibody-positive myasthenia gravis.

[0032] Thus, Th7R inhibits CXCR3 + Cell subpopulations and CXCR3 -Because it encompasses both CD4 and CD8 cell subpopulations, + When measuring the proportion of Th7R cells in a cell subpopulation, it is not essential to measure whether CXCR3 is expressed. However, as disclosed herein, CXCR3 - By gating on CCR4 for cell subpopulations, CD4 + This allowed for a clearer gate determination than when gating on CCR4 on the whole cells (see Example 5). Therefore, when measuring the Th7R cell subpopulation, 1. CD4 + CXCR3 in T cell populations - Selecting a cell subpopulation 2. CXCR3 - In a subpopulation of cells, CCR4 - Cell subpopulations and CCR4 + Gating of cell subpopulations 3. Using the set boundaries (gates), CD4 + CCR4 in T cell populations - CCR6 + Measuring the relative abundance of cell subpopulations; It has become clear from the present invention that the following series of steps is preferable.

[0033] (cancer) Examples of cancers that are targeted in the present invention include, but are not limited to, melanoma (malignant melanoma), non-small cell lung cancer, renal cell carcinoma, malignant lymphoma (Hodgkin's lymphoma or non-Hodgkin's lymphoma), head and neck cancer, urological cancer (bladder cancer, urothelial carcinoma, prostate cancer), small cell lung cancer, thymic cancer, gastric cancer, esophageal cancer, gastroesophageal junction cancer, liver cancer (hepatocellular carcinoma, intrahepatic cholangiocarcinoma), primary brain tumors (glioblastoma, primary central nervous system lymphoma), malignant pleural mesothelioma, gynecological cancer (ovarian cancer, cervical cancer, uterine cancer), soft tissue sarcoma, biliary tract cancer, multiple myeloma, breast cancer, and colorectal cancer.

[0034] (whole blood sample) Samples for fractionation and separation of T cells can be appropriately collected from a subject by a conventional method. For example, samples can be collected from the subject's peripheral blood, bone marrow, tumor tissue, hematopoietic tissue, spleen, normal tissue, lymph, etc. Collection of samples from peripheral blood can be advantageous because it is non-invasive and simple.

[0035] In the present invention, whole blood sample from peripheral blood or PBMC sample prepared therefrom can be used, and preferably whole blood sample can be used. Whole blood sample can be collected in anticoagulant-containing blood collection tube. In the present invention, any anticoagulant known in the art can be used, and preferably heparin, EDTA, sodium citrate, ACD-A, etc., and more preferably heparin.

[0036] As is clear from the examples in this specification, the preferred storage conditions for whole blood samples may vary depending on the cell marker to be measured. For Th7R, there was little variation in the measurement results even when stored over a wide range of temperatures and for a long period of time. + When measuring Th7R in cells, the whole blood sample can be stored at about 10°C to about 40°C, more preferably at about 12°C to about 25°C. When measuring Th7R, if the whole blood sample is stored at about 12°C to about 25°C, it can be measured sufficiently within one week (preferably within six days, more preferably within three days) from blood collection, which is unexpected compared to the cases of other markers described below. In addition, since whether or not the measurement can be performed immediately after blood collection depends on the blood collection location and blood collection facility, it can be advantageous that the measurement can be performed stably not immediately after blood collection but after one or more days have passed. Therefore, in the present invention, the storage period of the whole blood sample for measuring Th7R can be, for example, one day to one week, one day to six days, one day to three days, etc.

[0037] CD4 + CD62L in cells low It was found that a higher temperature range is preferable for measuring CD62L than for Th7R. lowWhen measuring CD62L, the whole blood sample can be stored at about 15°C to about 40°C, more preferably at about 18°C ​​to about 37°C. low When measuring CD4, if the whole blood sample is stored at about 18°C ​​to about 37°C, it can be measured sufficiently within one week after blood collection (preferably within three days after blood collection). In addition, since whether or not the measurement can be performed immediately after blood collection depends on the blood collection location and blood collection facility, it can be advantageous that the measurement can be performed stably not immediately after blood collection but after one or more days have passed. Therefore, CD4 + CD62L in cells low The storage period of the whole blood sample for measuring may be, for example, 1 day to 1 week, 1 day to 6 days, or 1 day to 3 days.

[0038] In certain embodiments, Th7R CD62L low It may be advantageous to measure the proportion of a cell subpopulation. In that case, the measurement can be performed adequately within one week (preferably within three days) of blood collection by storing the blood at about 18°C ​​to about 25°C. low The storage period of a whole blood sample for measuring cell subpopulations can be, for example, 1 day to 1 week, 1 day to 6 days, 1 day to 3 days, and the like.

[0039] On the other hand, CD4 + If blood is collected more than two days after the blood draw, the CCR7 in cells will vary greatly from the results measured immediately after blood draw. + When measuring CCR7 in cells, it was found that whole blood samples were not suitable for storage for more than three days. For storage up to two days, a temperature between 18°C ​​and 25°C was stable.

[0040] For CD8+ cells, the CD8 fluorescence intensity remained stable for a maximum of 2 days. For short periods of 2 days or less, a temperature of 18 to 25°C was suitable.

[0041] As described above, the storage temperature and storage period of whole blood samples vary depending on the type of cell and the type of marker to be measured, but it has been revealed that Th7R can be stored over an unexpectedly wide temperature range (about 10°C to about 40°C, more preferably about 12°C to about 25°C) and for long periods of time (within one week, preferably within six days, more preferably within three days from blood collection, for example, 1 day to 1 week, 1 day to 6 days, 1 day to 3 days, etc.).

[0042] The amount of blood collected for the whole blood sample can be an amount generally used in the field, typically about 16 ml or less. However, as shown in Example 6 of the present specification, even with a small amount of about 100 μl, the measurement of Th7R could be stably achieved. This amount is advantageous because the subject can collect blood by himself, and the burden on the subject is small. Therefore, in a preferred embodiment of the present invention, the amount of whole blood sample is about 10 μl or more, about 50 μl or more, more preferably about 100 μl or more, and about 500 μl or less, more preferably about 200 μl or less, and preferably about 100 μl to 150 μl. Examples of kits that can be used for collecting whole blood samples of the present invention include MBS Capillary (Lithium Heparin, 100-150 μl collection line) (Micro Blood Science Co., Ltd.), Micro Blood Collection Tube Lithium Heparin (without separation agent) 250 μ "Micro Health Tube" (Health Wave Japan Co., Ltd.), Capiject II (Terumo), BD Microtainer (registered trademark) Micro Blood Collection Tube BD Microguard TM Examples include, but are not limited to, capped.

[0043] In the past, in order to identify Th7R, a medical professional would collect blood, immediately separate it into PBMCs, freeze and store it as necessary, and transport the sample to the location where it was measured. In this case, a safety cabinet, a refrigerated centrifuge, and an ultra-low temperature freezer were required at the location where the blood was collected, and specialized equipment such as a safety cabinet, a refrigerated centrifuge, a CO2 incubator, an ultra-low temperature freezer, and a liquid nitrogen tank were required at the measurement location. Even if the blood was measured at the location where it was collected, a safety cabinet and a refrigerated centrifuge were required, and if the remainder used in the measurement was to be stored, an ultra-low temperature freezer and a liquid nitrogen tank were also required. However, when a whole blood sample can be used as in the present invention, only a microcentrifuge is required if the measurement is performed at the location where the blood was collected. If a whole blood sample is used and then the sample is transported to a measurement facility, no equipment is required at the blood collection location. This has a significant advantage over conventional methods.

[0044] As shown in the comparative examples, when a stabilizer was added to anticoagulated blood to fix cells, there were problems with detecting CD4 and CXCR3, so the efficient method for measuring Th7R in whole blood samples found in this specification was unexpectedly advantageous.

[0045] In a preferred embodiment, the whole blood sample is not subjected to either or both of hemolysis and centrifugation before measurement by a measuring device such as a flow cytometer. In the analysis of white blood cells (T cells in the present invention) in a whole blood sample, leakage of data from red blood cells present in large quantities can be a problem. In many cases, hemolysis and centrifugation are performed to remove red blood cells, but these operations are cumbersome and may cause damage to cells, loss, and aggregation. In the present invention, a method for simply measuring blood without hemolyzing or washing the blood (No-Wash, No-Lyse method) may be used. In the No-Wash, No-Lyse method, whole blood is dispensed (about 5 to 10 μl), antibody reaction is performed, and measurement is performed after dilution with a buffer. In the measurement, white blood cells may be separated using a violet laser or by trigger staining.

[0046] For example, it is possible to separate white blood cells from a whole blood sample by simultaneously using side-scattered light (SSC) from a blue laser and a violet laser. White blood cells and red blood cells have different scattering properties in the violet laser, and red blood cells absorb the light of the violet laser, resulting in a lower light intensity than white blood cells.

[0047] Alternatively, white blood cells can be separated from whole blood samples by staining to distinguish them from other cells. Red blood cells and other cells can be gated out by using the white blood cell marker CD45 antibody or markers specific to each cell group. In addition, since red blood cells and platelets do not have nuclei, cell-permeable dyes (Invitrogen) that can specifically stain the nuclei while they are still alive can be used. TM , Vybrant TM , DyeCycle TM By using a dye, it is possible to specifically stain only white blood cells.

[0048] (PBMC) When measuring cell subpopulations such as Th7R, if a long period of time (e.g., more than one week) is required between blood collection and cell fractionation and measurement, PBMCs can be isolated and frozen, thawed when fractionating and measuring cells, and cultured as necessary for use. In this case, as shown in Example 5 herein, separating PBMCs after a certain amount of time has passed since whole blood collection is not preferable for measuring Th7R. Therefore, in the present invention, when measuring cell markers such as Th7R from isolated PBMCs, it is preferable to isolate PBMCs within 3 hours, more preferably within 2 hours, after blood collection, and store them frozen.

[0049] Isolation and cryopreservation of PBMCs can be performed by methods known in the art, for example, using a vacutina spuit. TM Mononuclear cells can be isolated using and cryopreserved using liquid nitrogen (see Example 1).

[0050] (Cell fractionation and separation) CXCR3 +CCR4 - CCR6 + T cell subpopulations and CXCR3 - CCR4 - CCR6 + To count the number of cells in a cell subpopulation, such as a T cell subpopulation, cells other than the subpopulation may be experimentally removed from the total cells. For example, CD4 + Cells corresponding to the desired T cell subpopulation may be isolated from peripheral blood without using a specific antibody, such as the Effector Memory T cell Isolation Kit, Human (Militenyi Biotech). For example, CD4 + By using the Effector Memory T cell Isolation Kit, Human (Militenyi Biotech), CD4 cells can be isolated from peripheral blood without using CD4 and CD62L antibodies. + CD62L low Cells representing T cell subpopulations can be isolated. The total number of live cells can be counted and recorded, and the number of cells obtained using this kit can be counted and recorded. A similar kit is available: CD4+CD25+CD127dim / -Regulatory T cell Isolation Kit, Human (Militenyi Biotech), CD25 + CD49d-Regulatory T cell isolation kit, human (Militenyi Biotech) may also be selected. In one embodiment of the present invention, any kit can be used as long as it can measure the number of cells of each of the target T cell subpopulations.

[0051] It is also not necessary to use antibodies. Antibodies can specifically recognize and bind to molecules expressed in individual cells, and when the antibodies bind to molecules expressed on the cell surface or inside the cell, they are colored to detect the number of colored cells. Here, the molecules expressed on the cell surface or inside the cell are proteins, so when the protein is expressed, the mRNA encoding it is also produced inside the cell. In other words, it is sufficient to examine the mRNA in each cell to check the presence or absence of the mRNA encoding the protein molecule of interest. This is made possible by single-cell gene expression analysis, that is, mRNA analysis at the single-cell level. Examples of single-cell gene expression analysis include 1) next-generation sequencing using Quartz-Seq, 2) isolating cells using Fluidigm C1 System or ICELL8 Single-Cell System and preparing libraries using SMART-Seq v4, 3) isolating cells using a cell sorter and measuring by quantitative PCR using the Ambion Single Cell-to-CT kit, and 4) CyTOF SYSTEM (Standard Biotools).

[0052] That is, blood is collected, the number of live cells is counted, and the cells are separated using a cell sorter or the like. For each separated cell, the expression level of a specific gene can be measured using a quantitative PCR device, for example, using the Ambion Single Cell-to-CT kit. Based on the results, it can be determined whether each cell expresses CXCR3 + CCR4 - CCR6 + T cell subpopulations and CXCR3 - CCR4 - CCR6 + It is also possible to determine which T cell subpopulations the cells fall into and count the number of cells that fall into each subpopulation.

[0053] In the present invention, the measurement of the proportion of a cell subpopulation or comparison with a reference value or threshold value may be performed using a standard sample having a specified signal. The amount or proportion of a cell subpopulation in a sample can be measured by comparing the signal between a standard (e.g., particles attached with a fluorescent dye) prepared to generate a fluorescent signal corresponding to a predetermined cell subpopulation and a sample containing a cell population, and comparing with the standard. In addition, the presence or absence or amount of the marker of the present invention in the T cell composition in a sample can be determined by comparing the signal between a standard (e.g., particles attached with a fluorescent dye) prepared to generate a fluorescent signal corresponding to a predetermined reference value or threshold and a sample containing a cell population, and comparing with the standard.

[0054] In the present invention, when determining whether a particular marker is high (high expression) or low (low expression), a person skilled in the art can use classification criteria for expression intensity commonly used in the art. For example, for CD62L, the signal intensity corresponding to the 10E2 signal when a PE-labeled anti-human CD62L antibody is used as the boundary, low and CD62L high It is possible to clearly separate the above (WO2018 / 147291).

[0055] In one embodiment of the present invention, one skilled in the art can appropriately identify the surface markers of the indicated cells to fractionate or count the cells.

[0056] In this specification, "flow cytometry" refers to a technique for measuring the number of cells, individuals, and other biological particles suspended in a liquid, as well as the physical, chemical, and biological properties of each particle. Flow cytometry is now being used to analyze a variety of cells. In particular, flow cytometry has made it possible to determine the differentiation of blood cells. Such differentiation determination is beginning to be used not only for research purposes but also for diagnosis. Advantages of flow cytometry include, for example, the ease of determining the proportion of blast cells, high specificity and sensitivity, high reproducibility, the ability to analyze a large number of cells, and the short time required.

[0057] A device that uses this technology is called a "flow cytometer." A flow cytometer is an instrument that measures the optical properties of suspended matter (cells) in a uniform suspension of cells. The cells are carried by the liquid flow and pass through the focus of a laser light, and as they pass, the optical properties of forward scattered light, side scattered light, and fluorescence of one or more different wavelengths are measured simultaneously for each individual cell, 500 to 4,000 cells per second, and biological properties such as the size, internal structure, and the amount of various antigens or nucleic acids present in the cell membrane, cytoplasm, and nucleus can be measured quickly and accurately.

[0058] Scattered light is light that is scattered around when the laser hits a cell. Forward scattered light (FSC) is detected in front of the laser light axis, and the scattered light intensity is proportional to the surface area of ​​the cell. In other words, the larger the FSC value, the larger the cell, and the smaller the FSC value, the smaller the cell. Side scattered light (SSC) is detected at a position 90 degrees (right angle) to the laser light axis, and the scattered light intensity is proportional to the state of the cell's granules and intracellular structures. In other words, the larger the SSC value, the more complex the internal structure of the cell, and the smaller the SSC value, the more simple the internal structure of the cell.

[0059] The results of flow cytometry can typically be expressed as a dot plot with FSC on the X-axis and SSC on the Y-axis. Each cell is represented by a dot in the figure, and their positions are determined by the relative values ​​of FSC and SSC. Lymphocytes, which are relatively small in size and have a simple internal structure, are displayed in the lower left, granulocytes, which are large in size and have granules inside, are displayed in the upper right, and monocytes, which are large in size but have a simple internal structure, are displayed as separate groups between lymphocytes and granulocytes.

[0060] Fluorescence is the light emitted when a fluorescent dye labeled on a cell is excited by irradiated laser light and releases energy. A flow cytometer (for example, product name: Becton & Dickinson FACSCalibur) typically irradiates a single-wavelength laser light of 488 nm and a single-wavelength laser light of 635 nm. Although cells themselves have the property of emitting weak fluorescence (autofluorescence), in order to specifically detect molecules contained in cells using fluorescence, it is necessary to bind a fluorescent dye to the cell or the molecules contained in the cell in some way beforehand. For example, FITC (fluorescein isothiocyanate) absorbs excitation light of 488 nm and emits fluorescence (green) mainly at 530 nm. If an antibody is labeled with FITC in advance, the amount of antibody that binds to the cell will differ depending on the amount of antigen present on the cell surface, and as a result, the fluorescence intensity of FITC will differ, making it possible to estimate the amount of antigen present on the cell surface. An exemplary FACSCalibur is equipped with four fluorescence detectors capable of detecting different fluorescence wavelength ranges, and if multiple fluorescent dyes emitting light of different wavelengths are prepared, it is possible to simultaneously detect up to four different antigens. As fluorescent dyes other than FITC excited by a single-wavelength laser light of 488 nm, PE (phycoerythrin) mainly emits fluorescence at 585 nm, and PerCP (peridinin chlorophyll protein) and PE-Cy5 (carbocyanin-5) mainly emit fluorescence at 670 nm. APC (allophycocyanin), a fluorescent dye excited by a single-wavelength laser light of 635 nm, mainly emits fluorescence at 670 nm. These fluorescent dyes are combined with various antibodies and used for double staining or triple staining of cells. CD4, CD8, CD62L, CD25, CCR4, CCR6, CXCR3 molecules expressed on the surface of T lymphocytes can be detected by monoclonal antibodies that specifically react with these molecules.

[0061] In the method of the present invention, the expression pattern of the cell marker can be determined by any method for analyzing the distribution of expression of a marker protein, such as a flow cytometer, gene analysis, CyTOF, etc. Typically, the expression pattern of the cell marker in the method of the present invention can be determined on a cell distribution diagram showing the results of a flow cytometer (also called flow cytometry), such as a histogram or dot plot. In particular, CXCR3 - In the cell distribution map of cell subpopulations, CCR4 - Cell subpopulations and CCR4 + Set boundaries (gating) for cell subpopulations and use those boundaries (gates) to detect CD4 + CCR4 in T cell populations - CCR6 + The relative abundance of cell subpopulations is determined.

[0062] Strictly speaking, there are two types of flow cytometers: those that only analyze cells, and those that can separate (sort) the analyzed cells, the latter of which is called "FACS." In this specification, "FACS" is an abbreviation for fluorescence-activated cell sorter, and refers to a device used in a method of analyzing surface antigens of free cells such as lymphocytes using laser light, or separating certain cells based on the presence or absence of surface antigens.

[0063] The results of flow cytometry can be expressed by distributing cells as a distribution map of light originating from particles, such as a histogram or a dot plot (scatter diagram), for one measurement item or for two or more measurement items based on the detected optical information. In this specification, a "histogram" refers to a graph in which the intensity of the optical signal of each parameter is on the X axis and the number of cells is on the Y axis in fluorescence measurement using a flow cytometer. With this form, it is possible to count a total of 10,000 or more cells. In this specification, a "dot plot" refers to a plot in which the fluorescence intensity of two types of fluorescent dyes is on the X axis and the Y axis. In the case of double staining and triple staining, the fluorescence intensity of each is placed on the X axis or the Y axis, and analysis can be performed using a display method in which each cell corresponds to each point on a two-dimensional graph. In this specification, "gating," "setting a boundary," or "gating" refers to selecting a certain distribution area in the distribution map according to the measurement item in order to perform an appropriate measurement according to the measurement item.

[0064] For example, after peripheral blood or bone marrow fluid is collected, red blood cells are removed by hemolysis or density centrifugation, then the cells are reacted with fluorescently labeled antibodies (antibodies against the target antigen and their control antibodies), thoroughly washed, and then observed using flow cytometry. The detected scattered light and fluorescence are converted into electrical signals and analyzed by computer. The results show that lymphocytes, monocytes, and granulocytes can be distinguished by the strength of FSC representing the size of the cells and the strength of SSC representing the intracellular structure. After that, gate on the target cell population as necessary, and examine the cell marker expression patterns in those cells.

[0065] In practicing the methods of the present invention, one skilled in the art can appropriately identify the indicated cell surface markers to fractionate or count the cells.

[0066] As described above regarding the No-Wash, No-Lyse method, the present invention aims to measure the ratio of a specific cell subpopulation in T cells using whole blood or PBMC as a target. Therefore, data analysis may be facilitated by adding a CD45 antibody. The CD45 antibody reacts with lymphocytes including T cells and does not react with red blood cells and platelets. Therefore, the measurement target is preferably CD45. bright By limiting the analysis to a cell subpopulation, unnecessary cells such as red blood cells and platelets can be excluded from the analysis.

[0067] (kit) In one embodiment of the present invention, the kit of the present invention can include detection agents for CD4, CCR4, and CCR6 for use with samples prepared according to the method of the present invention, and in other embodiments, the kit of the present invention can further include detection agents for CXCR3, CD62L. In one embodiment, the detection agent is an antibody. Preferably, the antibody is appropriately labeled to facilitate detection of the marker.

[0068] (General technology) The molecular biological, biochemical and microbiological techniques used herein are well known and commonly used in the art, and may be any of the techniques described in, for example, Sambrook J. et al. (1989). Molecular Cloning: A Laboratory Manual, Cold Spring Harbor and its 3rd Ed. (2001); Ausubel, FM (1987). Current Protocols in Molecular Biology, Greene Pub. Associat ES and Wiley-Interscience; Ausubel, FM (1989). Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience; Innis, MA (1990). PCR Protocols: A Guide to Methods and Applications, Academic Press; Ausubel, FM (1992). Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub.Associates;Ausubel,FM(1995).Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology,Greene Pub.Associates;Innis,MAet al.(1995).PCR Strategies,Academic Press;Ausubel,FM(1999).These methods are described in Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Wiley, and annual updates; Sninsky, JJ et al. (1999); PCR Applications: Protocols for Functional Genomics, Academic Press, Special Edition of Experimental Medicine: "Gene Introduction & Expression Analysis Experimental Methods" Yodosha, 1997, etc., and the relevant parts (possibly the entirety) of these are incorporated herein by reference.

[0069] In this specification, "or" is used when "at least one or more" of the items listed in the sentence can be employed. The same applies to "alternative." In this specification, when "within the range of" two values ​​is specified, the range includes the two values ​​themselves.

[0070] All references cited herein, including scientific literature, patents, patent applications, and the like, are hereby incorporated by reference in their entirety to the same extent as if each was specifically set forth.

[0071] The present invention has been described above by showing preferred embodiments for ease of understanding. The present invention will be described below based on examples, but the above description and the following examples are provided for illustrative purposes only and are not provided for the purpose of limiting the present invention. Therefore, the scope of the present invention is not limited to the embodiments or examples specifically described in this specification, but is limited only by the scope of the claims. EXAMPLES

[0072] (Measurement Panel) In this example, the panel shown in Table 1 below (WB panel 2 or WB panel 3) was used.

[0073] [Table 1]

[0074] Example 1 Comparison of whole blood method and PBMC isolation method Whole blood was collected using a blood collection tube containing an anticoagulant (sodium heparin), and the whole blood was immediately separated from PBMCs and frozen for comparison. The sample analyzed was 8 ml of heparinized blood collected from the same subject (H-34), which was then divided into two portions: one was the heparinized whole blood, and the other was used to separate PBMCs.

[0075] For the whole blood, 100 μl of whole blood was added with a staining antibody and stained at room temperature for 15 minutes in the dark. Next, 2 ml of lysing solution (Becton Dickinson, Cat. 349202) was added and the blood was left at room temperature for 10 minutes in the dark to hemolyze the red blood cells. The blood was then centrifuged at 500×g for 5 minutes at room temperature and the supernatant was discarded. An additional 2 ml of 2% FBS / PBS was added to suspend the blood, and the blood was centrifuged under the same conditions. This suspension and centrifugation was repeated once more, and the supernatant was removed before suspending the blood in 250 μl of 2% FBS / PBS and measuring.

[0076] On the other hand, to obtain PBMC, the remaining whole blood was transferred to a 15 ml conical tube, and twice the amount of saline was added to the blood volume and mixed. This mixture was dispensed into two Leucosep lymphocyte separation tubes (Greiner, Cat. 163288-013) and centrifuged at 800 × g for 15 minutes at room temperature. The upper layer consisting of plasma and cells was stirred by pipetting, and the contents of two Leucosep lymphocyte separation tubes were collected into one 50 ml conical tube. 15 ml of 5% FBS / PBS was added to the collected cell solution, and the solution was centrifuged at 500 × g for 5 minutes at 4 ° C. After removing the supernatant, 10 ml of 5% FBS / PBS was added and suspended, the number of cells was counted, and the cell solution was divided into one for measurement on the day and one for freezing.

[0077] For the samples to be measured on the day, 10 ml of 5% FBS / PBS was added again and centrifuged, after which the supernatant was removed, 50 μl of PBS was added to suspend the samples, and the samples were transferred to a FACS tube, where the staining antibody was immediately added, and the samples were stained at room temperature for 20 minutes in the dark. After that, 1 ml of 2% FBS / PBS was added and suspended, followed by centrifugation at 500×g and 4°C for 5 minutes, after which the supernatant was removed, 250 μl of 2% FBS / PBS was added to suspend the samples, and measurements were performed (this is the PBMC staining process). The above was taken as Fresh PBMC.

[0078] The frozen portion was centrifuged at 500×g for 5 minutes at 4°C, the supernatant was removed, and 1 ml of Cell Banker 2 was added and suspended. The entire amount was dispensed into a cryotube, placed in a BICELL cooled to 4°C, and then immediately placed in a deep freezer at -80°C. The next day, it was transferred to a liquid nitrogen tank and frozen. Five days later, it was thawed in a constant temperature water bath at 37°C, suspended in 12 ml of 10% FBS / RPMI1640 medium (Nacalai Tesque, Cat. 30264-85), centrifuged at 500×g for 5 minutes at 4°C, and the supernatant was removed. 10 ml of 10% FBS / RPMI1640 medium was added again to suspend, the number of cells was counted, and the cell solution was divided into two. One was centrifuged at 500×g for 5 minutes at 4°C, the supernatant was removed, and 100 μl of PBS was added and suspended, and the PBMC staining process was performed and measured. This was called Frozen. The other cell solution was dispensed into a 24-well plate and cultured at 37°C and 5% CO2 for 48 hours. After that, the entire amount of the culture solution containing the cells was collected in a 15 ml conical tube, PBS was added to make up to 10 ml, and the number of cells was counted. After that, it was centrifuged at 500 x g and 4°C for 5 minutes, the supernatant was removed, and 100 μl of PBS was added to suspend the cells, and a PBMC staining process was performed and measurements were performed. This was called PBMC Culture. The same applies hereafter.

[0079] The cells were stained with antibodies against CD45, CD4, CCR4, CCR6, and CXCR3 (Table 1, WB panel 2) and measured using a BD Fortessa X-20. TM (Becton Dickinson) for analysis and plotting.

[0080] The Fresh graphs for whole blood and PBMC are similar (Figure 1). + Scatter plot of CCR4 vs CCR6 for whole cells, CD4 + A histogram of CXCR3 in cells. - A scatter plot of CCR4 vs CCR6, and CXCR3. + The patterns for whole blood and fresh blood are similar. However, in all the figures, frozen PBMCs are different from whole blood and fresh PBMCs. There are three types of PBMC culture (CD4 + , CXCR3 - , CXCR3 + In the scatter plot of CCR4 vs CCR6, CCR6 shows an intermediate pattern between fresh and frozen PBMCs, while CCR4 + The histogram of CXCR3 is closer to that of frozen PBMC.

[0081] From the above, the following points became clear: · Whole blood is similar to fresh PBMCs. · When PBMCs are cryopreserved, they are different from whole blood and fresh, and even after culture they are different from fresh. · CXCR3 isolation deteriorates after cryopreservation and does not return even after culture. · CCR4 + The number of cells does not decrease even after cryopreservation, but decreases after culture. · CCR6 + The number of cells decreases after cryopreservation and returns to normal slightly after culture, but is still less than immediately after blood collection.

[0082] (Example 2: Examination of the effect of storage period) In this example, the storage period of whole blood was changed and measurement was performed to examine the effect of the storage period.

[0083] The whole blood samples were prepared as follows: immediately after collection, stored at room temperature (20-22°C) for 3 days, and stored at room temperature for 6 days. Immediately after collection or after storage, the whole blood was hemolyzed, stained, and measured. The whole blood sample (H-30) prepared in Example 1 and the whole blood sample (H-34) collected on a different day were used in the experiment. WB panel 2 was used as the measurement panel (Table 1). No significant difference was observed between the samples immediately after collection and after storage (Figure 2).

[0084] We further increased the number of samples, counted the number of Th7R cells, and compared the storage period of whole blood.

[0085] The whole blood sample (H-30) prepared in Example 1 and the whole blood sample (H-34) drawn on a different day were used consecutively. The results are shown in Table 2. H-34 in this table is the numerical value of the results in FIG. 2.

[0086] [Table 2]

[0087] Table 2 also compares whole blood with PBMC (bottom row of Table 2, "2. Whole blood method day 0, Fresh, Frozen, and Culture data after PBMC separation from whole blood"). The PBMC processing method is as described in Example 1. H-34 in the bottom row of Table 2 shows the results of Example 1 (Figure 1) in numerical form. WB panel 2 was used as the measurement panel. Histograms and scatter plots corresponding to Figure 1 were created for each specimen. FlowJo was used to draw the diagrams and obtain the cell counts. CXCR3 - and CXCR3 + The cell numbers were obtained in the histogram of CXCR3.

[0088] In the upper row of Table 2 (1. Whole blood stored at room temperature for 0, 3, and 6 days), CD4 + After getting 10,000 or more of the whole, we will use CD4 + The total was adjusted to 10,000.

[0089] In the lower part of Table 2 (2. Whole blood method, day 0, Fresh, Frozen, and Culture data after PBMC separation from whole blood), CD4 + The numbers shown are based on a total of approximately 10,000 samples.

[0090] Th1 / 17 is CXCR3 + In the scatter plot of CCR4 vs CCR6, - CCR6 + The number of cells in the CXCR3 region. + The percentages shown are based on the total number of samples taken.

[0091] CCR6 SP (Single positive) is CXCR3 - In the scatter plot of CCR4 vs CCR6, - CCR6 + The number of cells in the CXCR3 region. - The percentages shown are based on the total number of samples taken.

[0092] Th7R represented the total number of Th1 / 17 and CCR6 SP.

[0093] Th1 is CXCR3 + In the scatter plot of CCR4 vs CCR6, - CCR6 - These are cells in the CXCR3 region. + The percentages shown are based on the total number of samples taken.

[0094] CCR4 + CCR6 - , CXCR3 + In the scatter plot of CCR4 vs CCR6, + CCR6 - These are cells in the CXCR3 region. + The percentages shown are based on the total number of samples taken.

[0095] TP (triple positive) is CXCR3 +In the scatter plot of CCR4 vs CCR6, + CCR6 + These are cells in the CXCR3 region. + The percentages shown are based on the total number of

[0096] TN (triple negative) is a condition characterized by the expression of CXCR3 - In the scatter plot of CCR4 vs CCR6, - CCR6 - These are cells in the CXCR3 region. - The percentages shown are based on the total number of

[0097] Th2 is CXCR3 - In the scatter plot of CCR4 vs CCR6, + CCR6 - These are cells in the CXCR3 region. - The percentages shown are based on the total number of

[0098] Th17 is CXCR3 - In the scatter plot of CCR4 vs CCR6, + CCR6 + These are cells in the CXCR3 region. - The percentages shown are based on the total number of

[0099] (Consideration) 1. Differences depending on the number of days whole blood has been stored When whole blood was measured on the day of collection, after three days of storage at room temperature, and after six days of storage at room temperature, the CXCR3 + was decreased, whereas CXCR3 of Th1 / 17 + The proportion of these tumors in the total tumors showed a slight tendency to increase (Table 2). - increased, whereas CXCR3 in CCR6 SP - The proportion of Th7R, which is the sum of Th1 / 17 and CCR6 SP, also increased slightly. + is decreased, CXCR3 - Increased, Th7R CCR4 - CCR6 +However, as can be seen from Figure 2, the increase or decrease was small, and as will be described later, the data is closer to that of Fresh PBMCs than that of Frozen and Culture PBMCs. In other words, it can be seen that the change during storage of whole blood is smaller than that of other processing methods.

[0100] CXCR3 + Th1 and CXCR3 - TN, i.e. CCR4 - CCR6 - The proportion of CCR4 increased slightly. - CCR6 - The proportion of people with disabilities increased.

[0101] CXCR3 + CCR4 in + CCR6 - and CXCR3 - The proportion of Th2 in the thymocytes decreased. + CCR6 - The proportion of

[0102] CXCR3 + TP(CCR4 + CCR6 + ) and CXCR3 - The proportion of Th17 in both groups decreased.

[0103] When we look at the ratios of CCR4 vs. CCR6 in conjunction with the results of Th1 / 17 and CCR6 SP, the trend in increase or decrease in the ratios is consistent regardless of whether CXCR3 is negative or positive. - CCR6 - and CCR4 - CCR6 + Increased, CCR4 + CCR6 - and CCR4 + CCR6 + This means that CCR4 + Decreased CCR4 - was increased, although the difference was not as large as when compared with PBMC.

[0104] 2. Comparison of whole blood and PBMCs Compared with fresh PBMCs, whole blood has a higher CXCR3 + Many, CXCR3 - (Table 2). Th1 / 17, CCR6 SP, and Th7R were also slightly more prevalent, but the differences were small.

[0105] In addition, when looking at the percentage of cells in the regions divided by CCR4 vs. CCR6, the results showed that in whole blood, compared with fresh PBMCs, Th1, TP, and TN were almost the same, CXCR3+CCR4+CCR6- were less, Th2 was slightly less, and Th17 was slightly less. However, this difference was smaller than in comparison with frozen and cultured PBMCs.

[0106] Next, we compare frozen and cultured PBMCs. CXCR3 + Regarding CXCR3, the expression level of frozen PBMCs is significantly decreased in culture compared to fresh, although this varies depending on the specimen. - Frozen is close to Fresh, and Culture is more than Fresh. Looking at the ratio of Th1 / 17 to CXCR3+, Frozen in PBMC is significantly lower than Fresh, and Culture is higher than Frozen but lower than Fresh. The ratio of CCR6 SP is similar to Th1 / 17, Frozen is significantly lower, and Culture is slightly lower than Fresh. Regarding the number of Th7R, Frozen is significantly lower than Fresh, and Culture is higher than Frozen but lower than Fresh.

[0107] That is, CXCR3 +The number of Th1 / 17 cells was significantly decreased after cryopreservation, and the number of Th1 / 17 cells was significantly decreased after cryopreservation, and although it increased slightly after culture, it did not return to the level immediately after isolation. On the other hand, the proportion of CCR6 SP was significantly decreased by cryopreservation, and the proportion of CCR6 SP increased to the level before cryopreservation in some samples and only slightly after culture. In addition, when the number of CD4+ cells was fixed and measured, the proportion of CXCR3 SP was significantly decreased after culture compared to immediately after isolation. - The number of Th1 / 17 and CCR6 SP increased in some samples, while the number of CCR6 SP increased in others. Therefore, Th7R, which is the sum of Th1 / 17 and CCR6 SP, decreased after cryopreservation and increased after culture, but did not return to normal until immediately after isolation. In other words, when measuring Th7R in PBMCs, it is desirable to measure it immediately after isolation and before cryopreservation.

[0108] Next, we compared CCR4 and CCR6 in the frozen and cultured PBMCs. - CCR6 + We compared cells in the other regions. + The ratio of CCR4 to CCR4 is slightly higher for Frozen than for Fresh, and for Culture it is slightly lower than Frozen but higher than Fresh. + CCR6 - The proportion of increased in Frozen and significantly decreased in Culture. The proportion of TP significantly decreased in Frozen and increased in Culture, but was significantly smaller than Fresh. CXCR3 - For TN, Th2, and Th17, the expression patterns of CCR4 and CCR6 were similar to those of CXCR3 + Th1 and CCR4, respectively + CCR6 - The same trend was observed for the increase and decrease in TP. This also applies to the relationship between Th1 / 17 and CCR6 SP. In other words, the effects of cryopreservation and culture were not related to the presence or absence of CXCR3. + CCR6 cells were not affected by cryopreservation but decreased during culture. + The number of CCR4 cells decreased when cryopreserved and recovered when cultured. + CCR6 + is CCR4+ cells, CCR6 + There was a depletion effect on both cells, with a decrease in cryopreservation and no recovery after culture.

[0109] (Example 3 Effect of storage period (2)) Using the data from Example 2, a comparison was made by counting the number of Th7R cells.

[0110] [Table 3]

[0111] The left side of Table 3 (whole blood) is the same as the upper row of Table 2 (1. Whole blood stored at room temperature for 0, 3, and 6 days), and the right side (whole blood and PBMC) is the same as the lower row of Table 2 (2. Whole blood method day 0, Fresh, Frozen, and Culture data after PBMC separation from whole blood). WB panel 2 (Table 1) was used for the measurements.

[0112] Here, we did not separate cells by CXCR3, but by CD4 + A scatter plot of CCR4 vs. CCR6 was drawn for the whole group. This plot is shown in Figures 1 and 2. Similar plots were drawn using FlowJo for the cells other than those shown in Figures 1 and 2, and the cell numbers were counted. CXCR3 - / + Since we did not separate Th7R cells, only the number of Th7R cells is shown (Table 3).

[0113] For whole blood, no significant differences were observed immediately after collection or after storage. In other words, no problems occurred with the measurement even six days after blood collection.

[0114] The Th7R expression in fresh PBMCs was slightly lower than that in whole blood.

[0115] Th7R in frozen PBMCs was reduced more than in whole blood or fresh PBMCs. The number of cultures obtained afterwards did not return to the level of whole blood or fresh PBMCs.

[0116] That is, when separating into PBMCs, Th7R measurement must be performed immediately after separation. When whole blood was stored and then PBMCs were separated, desirable measurement results were not obtained (see Example 5), so it is desirable to separate PBMCs immediately after blood collection and perform measurement immediately. On the other hand, when whole blood is used, results comparable to those obtained immediately after blood collection were obtained even 6 days later, making it clear that it is also possible to transport the blood at room temperature for 6 days and then perform measurement.

[0117] (Example 4 Effect of storage temperature (3)) In this example, the optimal temperature range for storing whole blood was investigated. The test was performed twice. In the first test, measurements were taken at 10, 15, 20, 25, 30, and 37°C and after 1, 2, 3, and 6 days. In the second test, measurements were taken at 12, 15, and 18°C ​​and after 1, 3, and 6 days. 250 μl of heparinized blood was dispensed into CRYOtubes and stored in a water bath or incubator set to each temperature. WB panel 2 and WB panel 3 were used for the measurements (Table 1).

[0118] In the first test, when stored at 15°C, it was thought that water droplets had formed on the inside of the lid, causing the blood portion to become concentrated. Therefore, a second test was conducted in which measures were taken to maintain the temperature so that water droplets would not form.

[0119] 1. Expression of CD4 and CD8 A scatter plot of CD4 vs. CD8 after storage at different temperatures and for different days is shown in Figure 3. The horizontal axis shows the distribution of CD4, and the vertical axis shows the distribution of CD8.

[0120] The conditions within the box in Figure 3 were evaluated as stable. + Based on the frequency and staining pattern, CD8 was stable for 3 days at temperatures between 12 and 25°C. In addition, the CD8 fluorescence intensity decreased after 2 days at all temperatures, suggesting that the expression level of CD8 had decreased. In the subsequent analysis, the CD8 expression level was determined according to the decrease in fluorescence intensity. + The gating range has been moved.

[0121] 2.Expression of CD62L on CD4 CD4 + The staining pattern of CD62L for the cells was shown in a histogram (Figure 4). The horizontal axis shows the distribution of CD62, and the vertical axis shows the count.

[0122] The conditions within the box in Figure 4 were evaluated as stable. low Regarding the staining, it was found that the higher the temperature, the better the separation over time. Also, at temperatures close to 37°C, the staining was stable even after increased storage days.

[0123] 3.Expression of CD62L on CD8 CD8 + The staining pattern of CD62L for the cells was shown in a histogram (Figure 5). The horizontal axis shows the distribution of CD62, and the vertical axis shows the count.

[0124] The conditions within the box in Figure 5 were evaluated as stable. CD8 + The cells are CD8 + If the position of CD8 is decreased, the range is shifted accordingly. + Cells were selected. CD4 + As with cells, staining remained stable with increasing storage days at temperatures close to 37°C, but there was an overall decrease in the intensity of fluorescence beyond 2 days.

[0125] 4. Expression of Th7R on CD4 CD4 + For cells, CCR4 - CCR6 + A histogram was created focusing on the cells that fell into the fraction, i.e., Th7R cells (Figure 6). The horizontal axis shows the distribution of CCR6, and the vertical axis shows the distribution of CCR4.

[0126] The conditions within the box in Figure 6 were evaluated as stable. Th7R was successfully measured over a wide range of storage temperatures over long storage periods, including 3 days.

[0127] 5. Expression of CCR7 and CD45RA on CD4 CD4 +A scatter plot of CCR7 and CD45RA was created for the cells (Figure 7). That is, we observed central memory, effector memory, and naive cells. The horizontal axis shows the distribution of CCR7, and the vertical axis shows the distribution of CD45RA.

[0128] The conditions within the box in Figure 7 were evaluated as stable. The separation of CCR7 staining worsened with increasing storage time. Therefore, it is possible that effector memory cells (CCR7 - CD45RA - ) and effector cells (CCR7 - CD45RA + ) increased. Regarding CD45RA, expression tended to decrease at low temperatures, and the frequency was stable at around 20°C. + CD45RA + ) was best at around 20°C, and the frequency decreased at temperatures either lower or higher than that.

[0129] 6. Expression of CCR7 and CD45RA on CD8 CD8 + A scatter plot of CCR7 and CD45RA was created for the cells (Figure 8). That is, central memory, effector memory, naive, and EMRA cells were observed. The horizontal axis shows the distribution of CCR7, and the vertical axis shows the distribution of CD45RA.

[0130] The conditions within the box in Figure 8 were evaluated as stable. Expression of CCR7 and CD45RA was good up to the second day of storage and was almost the same as that on the first day, but from the second day onwards, expression of CCR7 decreased significantly and CD45RA also decreased slowly.

[0131] 7. Summary CD8 + For cell measurements, the CD8 fluorescence intensity remained stable for a maximum of 2 days. For short periods of time (less than 2 days), a temperature of 18 to 25°C was suitable.

[0132] CD4 was stable for 3 days at temperatures between 12°C and 25°C, but CD4 +The stability of each marker in the cells was varied individually.

[0133] For CD62L, the higher the temperature, the better the separation over time, and around 37°C was stable even with increasing storage days.

[0134] The separation of CCR7 staining deteriorated with increasing storage time. Temperature was stable at 18℃~25℃.

[0135] Th7R was successfully measured over a wide range of storage temperatures (12°C to 25°C) over long storage periods, including up to 3 days.

[0136] Example 5: Isolation of PBMCs from stored whole blood After measuring whole blood, we investigated the usability of the remaining samples. As mentioned above, if whole blood is stored as it is, some cell markers deteriorate and cannot be measured. Therefore, we investigated separating and storing PBMCs after storage.

[0137] Blood was collected from two healthy volunteers using heparin blood collection tubes. The following four types were prepared. #1: Measured immediately after blood collection. #2: #1 was measured after storing it at room temperature (20.4-21.0℃) for 3 days. #3: PBMCs were isolated from #2, frozen for 23 days, and then thawed before measurement. #4: #3 was cultured for 48 hours and then measured. WB panel 2 was used for the measurements (Table 1).

[0138] The results are shown in Figure 9.

[0139] The cell frequency obtained for each preservation method is shown in Table 4 below. Note that each item in Table 4 indicates the following. CD45: Ratio of CD45 to singlets Lymphocytes: Ratio of lymphocytes to CD45 CD4: Ratio of CD4 to lymphocytes CXCR3 + : CXCR3 + to CD4 ratio Th1 / 17: Ratio of Th1 / 17 to CD4 CXCR3 - : CXCR3 - to CD4 ratio CCR6 SP: Ratio of CCR6 SP to CD4

[0140] [Table 4]

[0141] CD4 + The results of comparing the expression of CCR4, CCR6, and CXCR3 in cells by each preservation method are shown in Figure 10.

[0142] Figures 9 and 10 are from the same specimen. Table 4 shows the cell frequency of the two specimens. According to Figure 9 and Table 4, CXCR3 + The number of cells was significantly reduced. The number of cells increased slightly by culturing #4, but was still small compared to the number of cells in #1 and #2 whole blood samples.

[0143] CXCR3 + CCR4 - CCR6 + Th1 / 17, which is a CXCR3 + The trend was the same as that of the control group, except that the ratio after incubation was closer to that before incubation.

[0144] Also, CCR6 SP (CXCR3 - CCR4 - CCR6 + ) also CXCR3 - Nevertheless, CXCR3 + There was a similar trend.

[0145] Figure 10 shows which markers were affected by the sample processing conditions. #1 was compared immediately after blood collection with #2 to #4. According to this figure, #2, which was stored for 3 days, had no difference in any markers compared to #1. Also, #3 and #4 had no difference in CCR4 compared to #1. However, CCR6 + and CXCR3 + #3 and #4 were significantly decreased compared to #1. #4 was slightly decreased compared to #3. + and CXCR3 + The number of cases increased, but it was still less than #1 and #2.

[0146] From the above, PBMCs isolated after 3 days showed a high + and CCR6 + It was shown that the amount of cells in the blood decreases, which may be undesirable for measuring CXCR3 and CCR6. Therefore, PBMCs separated after storing whole blood are not suitable for measuring Th7R. To preserve the blood, it is recommended to divide the blood into two immediately after collection, measure one of them as a whole blood sample including CD8 within two days, or measure the other as a whole blood sample without measuring CD8 within three days, and separate the remaining blood into PBMCs immediately after collection and store them frozen.

[0147] Example 6 Importance of CXCR3 Measurement The definition of Th7R is CCR4 - CCR6 + CD4 + and CXCR3 + CXCR3 - Therefore, in this Example, although it is considered that CXCR3 measurement is unnecessary in the measurement of Th7R, whether or not measurement of CXCR3 is significant was examined.

[0148] Blood was collected from six healthy subjects using heparin blood collection tubes and immediately measured using WB panel 2 (Table 1). Data analysis and graphing were performed using FlowJo. The results are shown in Figures 11A to 11D. Figure 11 shows the CD4 + or CXCR3 - CCR6 vs CCR4 scatter plot for cells. Figure 11A: CD4+ T cells. Gates not shown. Figure 11B: CXCR3 - CD4 + T cells. Gates not shown. Figure 11C: Same as Figure 11A. CXCR3 - The gate created in is shown. Figure 11D: Same as Figure 11B. CXCR3 - The gate created in is shown.

[0149] According to Figure 11B, depending on the specimen, CXCR3 - CCR4 high CCR6 - The cells were clearly distinct as a single population and expressed CXCR3 - CCR4 med CCR6 - On the other hand, according to Figure 11A, the CD4 + In the overall scatter plot, CCR4 high CCR6 - Cells and CCR4 med CCR6 - The separation between the two populations of cells is difficult to see. For this reason, in Figure 11B, high It is easy to determine the gate of this population, and the gate is determined in this figure as shown in FIG. 11D, and the gate is also shown in FIG. 11C.

[0150] Therefore, it is better to measure CXCR3. - Against CCR4 - CCR6 + It is easy to make a gate for CCR4. - CCR6 + This tendency was more pronounced when using whole blood samples than when using PBMCs, and CXCR3 expression was higher in whole blood samples than in PBMCs, especially when blood was collected more than 3 days ago. - Against CCR4 - CCR6 + It was easy to decide on the gate.

[0151] (Example 7) Measurement of self-collected blood samples using a microblood collection device Previous experiments have shown that whole blood can be measured, and that a small amount can be used. Therefore, in this example, the possibility of using a micro-blood sampling device was examined. With the micro-blood sampling device used in this example, subjects can easily sample blood themselves.

[0152] Blood was collected by pricking the fingertip with a BD safety lancet (Becton Dickinson) and collecting blood with an MBS capillary (lithium heparin, 100-150 μl collection line) (Micro Blood Science, Inc.). After blood collection, it was immediately stained with WB panel 3 (Table 1) and measured. The measurement results are shown in Figure 12. Measurement was possible without any problems even with a very small amount of blood collected, 100 μl to 150 μl.

[0153] It is now possible to measure samples taken by self-collecting 150μl of blood (approximately 3 drops). With this method, blood can be collected in the laboratory and measurements can be taken immediately, even when medical personnel are not present. With the conventional method using PBMCs, some panels required culture, which meant that controls could not be performed immediately. Also, in order to prepare controls daily, it was necessary to frequently collect around 16ml of blood from healthy individuals. However, with this method, it is possible to collect only 3 drops of blood when controls are required urgently.

[0154] (Comparative Example: Cell Immobilization) Paraformaldehyde (PFA) or BD Cell FIX (a solution containing 10.0% formaldehyde, 3.55% methanol, and 0.93% sodium azide) was added to the anticoagulated blood, which was then stored at a specified temperature for three days before being treated with PBMCs, stained, and measured.

[0155] (1) Paraformaldehyde Four 4ml blood collection tubes (Nipro, Cat. 31-764) were collected from two subjects (H-15, H-34) and treated with sodium heparin. Each was dispensed into 10 tubes of 1ml each. PBS was added to the 4% paraformaldehyde-phosphate buffer to prepare two tubes each with a final paraformaldehyde concentration of 0.5%, 1%, 1.5%, and 2%, and two tubes were left untreated. Each tube with a concentration of 0 to 2% was left at 4℃ or room temperature for three days.

[0156] For paraformaldehyde concentrations ranging from 0 to 2%, we added saline in an amount twice the volume of blood after bringing the solution to room temperature, and placed them in Leucosep lymphocyte separation tubes (Greiner, Cat. 163288-013).

[0157] The above tubes were centrifuged at room temperature at 800xg for 15 minutes. The upper layer consisting of plasma and cells was stirred by pipetting and collected in one 15ml conical tube. The collected suspension was added with 5ml or an equal amount of 5% FBS / PBS to the collected suspension, and centrifuged at 500xg for 5 minutes at 4℃. After removing the supernatant, 10ml of 5% FBS / PBS was added and the cells were suspended and counted.

[0158] On the same day, blood was collected from two 8 ml BD Vacutainers (blood collection tubes containing anticoagulant and separator (BD, Cat. 362753)) and treated with sodium heparin. The blood was centrifuged at 2,200 x g, 20 ° C, for 20 minutes, and the upper layer consisting of plasma and cells was stirred by pipetting and collected in one 50 ml conical tube. 15 ml of 5% FBS / PBS was added to the collected suspension, and the mixture was centrifuged at 500 x g, 4 ° C, for 5 minutes. After removing the supernatant, 10 ml of 5% FBS / PBS was added to suspend the blood and the number of cells was counted. The blood collected in the 8 ml Vacutainer was divided into a suspension for measurement on the day and a suspension for freezing.

[0159] The portion left for 3 days and the portion measured on the day using 8 ml of BD Vacutainer were counted, centrifuged, the supernatant removed, 50 μl of PBS added and suspended, then transferred to a FACStube, and staining antibodies were immediately added, and stained for 20 minutes in the dark at 4°C. Then, 1 ml of 2% FBS / PBS was added and suspended, followed by centrifugation at 500xg and 4°C for 5 minutes, the supernatant removed, and 250 μl of 2% FBS / PBS was added and suspended for measurement. The 8 ml of BD Vacutainer frozen material was centrifuged at 500xg for 5 minutes at 4℃, and after removing the supernatant, approximately 5.0 x 10 cells were collected per cryotube. 6 Cell Banker 2 was added to the cells to give a cell concentration of 1 / ml and suspended. This was dispensed into cryotubes in 1 ml portions, placed in BICELLs cooled to 4°C, and then immediately placed in a deep freezer at -80°C. The next day, the cells were transferred to a liquid nitrogen tank and frozen for storage. After two days, the cells were thawed in a constant temperature water bath at 37°C, suspended in 12 ml of 10% FBS / RPMI1640 medium (Nacalai Tesque, Cat. 30264-85), centrifuged at 500xg and 4°C for 5 minutes, and the supernatant was removed. After adding 10 ml of 10% FBS / RPMI1640 medium again and suspending the cells, the number of cells was counted, and the cell solution was dispensed into a 24-well plate and cultured at 37°C and 5% CO2 for 48 hours. The entire amount of the culture solution containing the cells was then collected in a 15 ml conical tube, and the number of cells was counted. After that, the mixture was centrifuged at 500xg and 4℃ for 5 minutes, the supernatant was removed, and 100μL of PBS was added to suspend the mixture. The PBMC staining process was carried out and the measurement was performed. This was called PBMC Culture. The same applies hereafter. The sample list is as follows. No. Sample name Details of leaving it for 3 days or other treatment 1 H-15 PBMC isolation, cryopreservation, and 2-day culture after thawing (PBMC Culture) 2 H-15 PBMCs not preserved after isolation (PBMC Fresh) 3 H-15 2% paraformaldehyde, 4°C 4 H-15 1.5% paraformaldehyde, 4°C 5 H-15 1% paraformaldehyde, 4°C 6 H-15 0.5% paraformaldehyde, 4°C 7 H-15 0% paraformaldehyde, 4°C 8 H-15 2% paraformaldehyde, room temperature 9 H-15 1.5% paraformaldehyde, room temperature 10 H-15 1% paraformaldehyde, room temperature 11 H-15 0.5% paraformaldehyde, room temperature 12 H-15 0% paraformaldehyde, room temperature 13 H-34 Cryopreservation after PBMC isolation, 2-day culture after thawing (PBMC Culture) 14 H-34 PBMCs not preserved after isolation (PBMC Fresh) 15 H-34 2% paraformaldehyde, 4°C 16 H-34 1.5% paraformaldehyde, 4°C 17 H-34 1% paraformaldehyde, 4°C 18 H-34 0.5% paraformaldehyde, 4°C 19 H-34 0% paraformaldehyde, 4°C 20 H-34 2% paraformaldehyde, room temperature 21 H-34 1.5% paraformaldehyde, room temperature 22 H-34 1% paraformaldehyde, room temperature 23 H-34 0.5% paraformaldehyde, room temperature 24 H-34 0% paraformaldehyde, room temperature The results were as follows:

[0160] <cd4> Room temperature: CD4 expression was not observed in any of the cells with PFA added to a final concentration of 2% to 1%. Even in the cells with PFA added to a final concentration of 1%, only weak expression was observed. 4℃: CD4 expression was not observed in any of the cells where PFA was added at a final concentration of 2-1%. Even in the cells where PFA was added at 0.5%, only weak expression was observed.

[0161] <cxcr3> Room temperature: Since CD4 was not expressed, a clear biphasic pattern of CXCR3 could not be confirmed. 4℃: As the PFA concentration was decreased from 2% to 0.5%, the CXCR3 expression peaked at 1%. + The proportion of these genes tended to increase, and expression was not stable.

[0162] <ccr6> Among the samples in which expression was confirmed, those in which PFA was added were compared with those in which CCR6 was not added. + Expression of 10 3 compared with about 10 4 A fairly high level of expression was confirmed, and the expression was not stable.

[0163] <ccr4> Among the samples in which expression was confirmed, those to which PFA was added had a narrower expression range and poorer separation than those to which PFA was not added.

[0164] (2)BD Cell Fix Blood was collected from two subjects (H-15, H-34) in one 4ml blood collection tube and treated with sodium heparin. Each was dispensed into four tubes of 1ml each. BD Cell FIX (BD, Cat. 340181: discontinued, now sold as Stabilizing Fixative 3X Concentrate) diluted with 2% FBS / PBS was added to the tubes to give final dilution ratios of x4, x10, and x20, and one tube was left untreated. These were left at 4°C for three days. The rest of the procedure was the same as for paraformaldehyde. That is, PBMCs were isolated. The sample list is as follows: No. Sample Name Processing 25 H-15 Cell without FIX, 4°C, 3 days 26 H-15 x4 Cell FIX, 4°C, 3 days 27 H-15 x10 Cell FIX, 4°C, 3 days 28 H-15 x20 Cell FIX, 4°C, 3 days 29 H-34 Cell No FIX, 4°C, 3 days 30 H-34 x4 Cell FIX, 4°C, 3 days 31 H-34 x10 Cell FIX, 4°C, 3 days 32 H-34 x20 Cell FIX 4°C, 3 days The results were as follows: 4-fold dilution: No lymphocyte regions are visible. 10x dilution: Lymphocyte regions are barely visible. 20-fold dilution: CD4 expression was visible, but it was lower than the usual expression position, and the CXCR3 cutoff was shifted to the left and was not stable.

[0165] As described above, there were problems with the detection of CD4 and CXCR3, especially when the cells were fixed by adding a stabilizer to anticoagulated blood, so an efficient method for measuring Th7R found in whole blood samples would be advantageous. [Industrial Applicability]

[0166] The present invention relates to a method for the treatment of + It can be used to measure the relative abundance of medically important cell subpopulations in a T cell population.

Claims

1. CD4 in a sample from a subject + CCR4 in T cell populations - CCR6 + 1. A method for determining relative abundance of cell subpopulations, comprising: The CD4 + CXCR3 in T cell populations - Selecting a cell subpopulation; CXCR3 - In a subpopulation of cells, CCR4 - Cell Subpopulations and CCR4 + establishing boundaries between cell subpopulations; Using the above boundary, CD4 + CCR4 in T cell populations - CCR6 + Measuring the relative abundance of cell subpopulations. The method includes:

2. The method of claim 1 , wherein the sample is a whole blood sample of peripheral blood or a peripheral blood mononuclear cell (PBMC) sample of the subject.

3. The method of claim 2 , wherein the sample is a whole blood sample.

4. The method of claim 3 , wherein the sample has been stored for one or more days after collection from the subject.

5. The method of claim 4, wherein the sample is stored for 1 to 6 days after collection from the subject.

6. The method of claim 4, wherein the sample is stored for 1 to 3 days after collection from the subject.

7. The method of claim 4, wherein the sample is stored at about 10°C to about 40°C.

8. The method of claim 4, wherein the sample is stored at about 12°C to about 25°C.

9. The method of claim 3, wherein the sample is from about 10 μl to about 500 μl.

10. CD4 in a sample from a subject + CCR4 in T cell populations - CCR6 + 1. A method for determining relative abundance of cell subpopulations, comprising: providing a whole blood sample from said subject; The CD4 + CCR4 in T cell populations - CCR6 + Measuring the relative abundance of cell subpopulations. The method includes:

11. The method of claim 10, wherein the sample has been stored for one or more days after collection from the subject.

12. The method of claim 11, wherein the sample is stored for 1 to 6 days after collection from the subject.

13. The method of claim 11, wherein the sample is stored for 1 to 3 days after collection from the subject.

14. The method of claim 11, wherein the sample is stored at about 10°C to about 40°C.

15. The method of claim 11, wherein the sample is stored at about 12°C to about 25°C.

16. The method of claim 10, wherein the sample is from about 10 μl to about 500 μl.

17. A kit for use in the method of any one of claims 1 to 16, comprising a detection agent for CD4, a detection agent for CCR4 and a detection agent for CCR6.

18. 18. The kit of claim 17, further comprising a detection agent for CXCR3.

19. The kit of claim 16 , wherein the detection agent is an antibody.

Citation Information

Patent Citations

  • Methods for identifying anti-gpr-9-6 and anti-teck antibodies and modulators of gpr-9-6 and teck function.

    JP2002542157A

  • Predicting response to immunotherapy

    JP2020533608A

  • Method and composition for predicting long-term survival in cancer immunotherapy

    WO2020171141A1

  • Biomarker for predicting response to cancer treatment

    WO2022054796A1

  • Immunological biomarker for predicting clinical effect of cancer immunotherapy

    WO2018147291A1